NANOFORM FINLAND OYJ

Nanoform reduced cash burn to EUR 1.5m in Q2 (EUR 5m H1) and is targeting cash outflow below EUR 10m for 2026. Operating costs fell 33% in H1 and the gross margin is above 90%. The company received positive regulatory feedback from the MHRA on nanoenzalutamide and plans to submit a first marketing authorisation application in 2026. An exclusivity agreement in the biologics area worth USD 1m was also signed; revenue will be recognised in staggered tranches over 12 months. » More on de.investing.com

Nanoform reported Q2 revenue of EUR 800,000 (+16% year-on-year), a gross margin of 84% and a gross profit of EUR 700,000. Adjusted loss per share narrowed and the EBITDA loss fell to EUR 3m, supported by 36% lower operating costs following layoffs and short-time work. The company signed an exclusivity agreement with a US biopharma partner for its nanoparticle technology and sees positive MHRA feedback as support for an accelerated approval pathway for nanoenzalutamide; it aims to file a first regulatory application before the end of 2026. For 2026 Nanoform targets a cash burn below EUR 10m and plans more signed non-GMP and GMP projects while continuing cost-saving measures. » More on de.investing.com

Nanoform reports a Q3 2025 cash burn of €3.9m versus €5.3m a year earlier and holds roughly €30m in liquid funds. The company received a commercial GMP manufacturing licence for nanoformulated APIs and is expanding its market presence in Asia. Nanoform aims to reduce annualised cash burn to under €10m by 2026. Despite positive operational progress, the stock fell 6.44% after the release and closed at $1.05. » More on de.investing.com